**Supplementary Table 2.** Changes from baseline to week 24 in secondary outcomes

| Outcome measure | Asian patients (n = 173) | | Caucasian patients (n = 371) | |
|---|---|---|---|---|
| | Placebo (n = 85) | Safinamide (n = 88) | Placebo (n = 188) | Safinamide (n = 183) |
| **DRS score** | | | | |
| Mean at baseline (SE) | 2.20 (0.30) | 2.61 (0.37) | 2.74 (0.23) | 2.89 (0.26) |
| LS mean (SE) | -0.10 (0.65) | 0.20 (0.61) | -0.32 (0.18) | -0.12 (0.18) |
| LS difference vs. placebo (95% CI) | 0.30 (-0.31, 0.90) | | 0.20 (-0.27, 0.67) | |
| p-value | 0.3309 (NS) | | 0.4117 (NS) | |
| **DRS score by subgroup** | | | | |
| DRS score at baseline > 0 | n = 51 | n = 53 | n = 119 | n = 114 |
| Mean at baseline (SE) | 3.67 (0.39) | 4.34 (0.48) | 4.33 (0.28) | 4.63 (0.32) |
| LS mean change from baseline (SE) | -1.01 (1.00) | -0.63 (0.93) | -0.88 (0.26) | -0.58 (0.26) |
| LS difference vs. placebo (95% CI) | 0.37 (-0.52, 1.27) | | 0.30 (-0.38, 0.99) | |
| p-value | 0.4103 (NS) | | 0.3843 (NS) | |
| DRS score at baseline = 0 | n = 34 | n = 35 | n = 69 | n = 69 |
| Mean at baseline (SE) | 0.00 (0.00) | 0.00 (0.00) | 0.00 (0.00) | 0.00 (0.00) |
| LS mean change from baseline (SE) | 1.07 (0.64) | 1.37 (0.64) | 0.55 (0.20) | 0.66 (0.21) |
| LS difference vs. placebo (95% CI) | 0.29 (-0.34, 0.93) | | 0.11 (-0.40, 0.61) | |
| p-value | 0.3622 (NS) | | 0.6747 (NS) | |
| **OFF-time after morning levodopa, hr** | | | | |
| Mean at baseline (SE) | 0.94 (0.07) | 0.91 (0.06) | 0.82 (0.05) | 0.79 (0.04) |
| LS mean change from baseline (SE) | -0.18 (0.19) | -0.40 (0.18) | -0.10 (0.05) | -0.26 (0.05) |
| LS difference vs. placebo (95% CI) | -0.22 (-0.40, -0.04) | | -0.16 (-0.28, -0.04) | |
| p-value | 0.0144 | | 0.0105 | |
| **CGI-C rating** | | | | |
| Mean at baseline (SE) | NA | NA | NA | NA |
| LS mean (SE) | 4.10 (0.33) | 3.75 (0.31) | 3.84 (0.08) | 3.36 (0.09) |
| LS difference vs. placebo (95% CI) | -0.35 (-0.66, -0.04) | | -0.48 (-0.70, -0.26) | |
| p-value | 0.0254 | | < 0.0001 | |
| **CGI-S rating** | | | | |
| Mean at baseline (SE) | 3.82 (0.06) | 3.77 (0.07) | 4.14 (0.05) | 4.04 (0.06) |
| LS mean (SE) | -0.22 (0.21) | -0.40 (0.20) | -0.07 (0.05) | -0.17 (0.05) |
| LS difference vs. placebo (95% CI) | -0.18 (-0.37, 0.01) | | -0.10 (-0.22, 0.03) | |
| p-value | 0.0699 (NS) | | 0.1302 (NS) | |
| **PGI-C rating** | | | | |
| Mean at baseline (SE) | NA | NA | NA | NA |
| LS mean change from baseline (SE) | 3.68 (0.30) | 3.28 (0.29) | 3.70 (0.09) | 3.34 (0.09) |
| LS difference vs. placebo (95% CI) | -0.40 (-0.68, -0.11) | | -0.36 (-0.58, -0.14) | |
| p-value | 0.0064 | | 0.0014 | |
| **UPDRS part II (ON phase) total score** | | | | |
| Mean at baseline (SE) | 8.25 (0.57) | 8.00 (0.54) | 11.38 (0.47) | 10.88 (0.41) |
| LS mean changes from baseline (SE) | -0.09 (1.08) | -0.52 (1.02) | -0.95 (0.28) | -1.44 (0.29) |
| LS difference vs. placebo (95% CI) | -0.43 (-1.43, 0.57) | | -0.48 (-1.22, 0.25) | |
| p-value | 0.4009 (NS) | | 0.1969 (NS) | |
| **UPDRS Part IV (items 32–34)** | | | | |
| Mean at baseline (SE) | 1.56 (0.20) | 1.55 (0.21) | 2.06 (0.15) | 2.07 (0.14) |
| LS mean (SE) | 1.10 (0.47) | 1.25 (0.45) | -0.38 (0.11) | -0.10 (0.11) |
| LS difference vs. placebo (95% CI) | 0.16 (-0.28, 0.59) | | 0.28 (-0.01, 0.58) | |
| p-value | 0.4786 (NS) | | 0.0575 (NS) | |
| **UPDRS Part IV (items 32–35)** | | | | |
| Mean at baseline (SE) | 1.87 (0.22) | 1.86 (0.23) | 2.43 (0.16) | 2.35 (0.16) |
| LS mean change from baseline (SE) | 0.87 (0.48) | 1.14 (0.46) | -0.37 (0.12) | -0.13 (0.12) |
| LS difference vs. placebo (95% CI) | 0.27 (-0.18, 0.72) | | 0.24 (-0.07, 0.55) | |
| p-value | 0.2398 (NS) | | 0.1290 (NS) | |
| **ESS** | | | | |
| Mean at baseline (SE) | 4.91 (0.39) | 5.52 (0.42) | 6.95 (0.33) | 7.03 (0.31) |
| LS mean change from baseline (SE) | 0.80 (1.16) | 0.69 (1.12) | -0.16 (0.25) | -0.36 (0.25) |
| LS difference vs. placebo (95% CI) | -0.11 (-1.00, 0.78) | | -0.20 (-0.84, 0.44) | |
| p-value | 0.8087 (NS) | | 0.5325 (NS) | |
| **QUIP** | | | | |
| Mean at baseline (SE) | 1.44 (0.35) | 1.66 (0.42) | 0.77 (0.15) | 0.79 (0.14) |
| LS mean change from baseline (SE) | -0.32 (0.82) | -0.50 (0.77) | 0.23 (0.18) | 0.15 (0.18) |
| LS difference vs. placebo (95% CI) | -0.18 (-0.97, 0.61) | | -0.08 (-0.53, 0.38) | |
| p-value | 0.6479 (NS) | | 0.7341 (NS) | |
| **EQ-5D index score** | | | | |
| Mean (SE) at baseline | 0.66 (0.02) | 0.67 (0.02) | 0.68 (0.02) | 0.69 (0.01) |
| LS mean changes from baseline (SE) | 0.02 (0.05) | 0.07 (0.04) | -0.04 (0.01) | 0.02 (0.01) |
| LS difference vs. placebo (95% CI) | 0.05 (0.01, 0.09) | | 0.06 (0.03, 0.10) | |
| p-value | 0.0184 | | 0.0010 | |

CI, confidence interval; CGI-C, Clinical Global Impression – Change; CGI-S, Clinical Global Impression – Severity; DRS, Dyskinesia Rating Scale; ESS, Epworth Sleepiness Scale; EQ-5D, EuroQoL Five Dimensions; LS, least squares; NA, not applicable; NS, not significant; PGI-C, Patient Global Impression – Change; QUIP, Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease; SE, standard error; UPDRS, Unified Parkinson's Disease Rating Scale.